ZEPOSIA

Peak

ozanimod hydrochloride

NDAORALCAPSULE
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Clinical Trials (2)

NCT06188637Phase 4Withdrawn

Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study

Started Aug 2024
0
Ulcerative Colitis
NCT05335031N/ACompleted

A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)

Started Mar 2021
450 enrolled
Multiple Sclerosis, Relapsing-Remitting

Loss of Exclusivity

LOE Date
Sep 30, 2038
153 months away
Patent Expiry
Sep 30, 2038
Exclusivity Expiry
Aug 30, 2027

Patent Records (5)

Patent #ExpiryTypeUse Code
8796318
May 14, 2029
SubstanceProduct
9382217
May 14, 2029
U-2774
10239846
Nov 15, 2030
U-3740
8481573
Mar 24, 2033
SubstanceProduct
U-2774
11680050
Sep 30, 2038
SubstanceProduct
U-3740